Intellia Stock Declines Despite Historic Gene-Editing Treatment Breakthrough

Cambridge, Monday, 27 April 2026.
Despite Intellia Therapeutics achieving an 87% reduction in swelling attacks with the world’s first inside-the-body gene-editing treatment, investor hesitation drove shares down 3% on Monday.